CMPX Q2 2024 Earnings — Compass Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CMPXCompass Therapeutics, Inc.

$781M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$850,000

Gross Profit

$850,000100.0% margin

Operating Income

-$15M-1770.0% margin

Net Income

-$13M-1538.4% margin

EPS (Diluted)

$-0.10

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$11M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$156M

Total Liabilities

$10M

Stockholders' Equity

$146M

Cash & Equivalents

$19M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$850,000	$0	—
Gross Profit	$850,000	$0	—
Operating Income	-$15M	-$13M	-12.8%
Net Income	-$13M	-$11M	-15.9%